-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 10, the official website of NMPA showed that Suzhou Tianma Medicine's octreotide acetate injection passed the consistency evaluation of generic drugs, and it was the third company that had passed the evaluation
.
According to data from Meinenet, the sales of terminal octreotide in China's public medical institutions will exceed 2.
7 billion yuan in 2020
.
Octreotide acetate is a synthetic octapeptide derivative of natural somatostatin.
Compared with natural somatostatin, it has a significantly longer half-life and has the same pharmacological effects.
It is often used for emergency treatment of esophageal-gastric varices bleeding caused by liver cirrhosis and to prevent pancreatic surgery.
Post-complication, relieve the symptoms and signs related to gastrointestinal pancreatic endocrine tumors
.
According to data from Mi Nei.
com, in 2020, China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal octreotide sales will exceed 2.
7 billion yuan; in 2021H1, its sales will exceed 1.
2 billion yuan.
The manufacturer Novartis occupies 61.
72% of the market share
.
Sales of terminal octreotide in China's public medical institutions (unit: 10,000 yuan) Source: Mynet.
com China's public medical institutions' terminal competition pattern.
Domestically marketed octreotide products include octreotide acetate injection, octreotide acetate for injection, and octreotide acetate microspheres for injection
.
Among them, there are as many as 17 manufacturers of octreotide acetate injection, but only three companies, including Sihuan Pharmaceutical, Sinopharm Yixin Pharmaceutical, and Suzhou Tianma Pharmaceutical, have been evaluated
.
At present, there are still many companies whose supplementary applications for the consistency evaluation of octreotide acetate injection are under review, including Shanghai First Biochemical Pharmaceutical Co.
, Ltd.
, Xinghao Pharmaceutical Co.
, Ltd.
, Chengdu Shengnuo Biological Co.
, Ltd.
, Hainan Zhonghe Pharmaceutical Co.
, Ltd.
, and Wuhan Renfu Pharmaceutical Co.
, Ltd.
and so on
.
In addition, four companies including Huiyu Pharmaceutical, Fuan Pharmaceutical, Harbin Sanlian Pharmaceutical, and Hanyu Pharmaceutical have also submitted applications for the imitation of octreotide acetate injection in four categories
.
It is worth noting that octreotide acetate injection has met the requirements for centralized procurement and is expected to be included in the national centralized procurement in the future
.
Data source: Mi Neiwang database, NMPA
.
According to data from Meinenet, the sales of terminal octreotide in China's public medical institutions will exceed 2.
7 billion yuan in 2020
.
Octreotide acetate is a synthetic octapeptide derivative of natural somatostatin.
Compared with natural somatostatin, it has a significantly longer half-life and has the same pharmacological effects.
It is often used for emergency treatment of esophageal-gastric varices bleeding caused by liver cirrhosis and to prevent pancreatic surgery.
Post-complication, relieve the symptoms and signs related to gastrointestinal pancreatic endocrine tumors
.
According to data from Mi Nei.
com, in 2020, China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal octreotide sales will exceed 2.
7 billion yuan; in 2021H1, its sales will exceed 1.
2 billion yuan.
The manufacturer Novartis occupies 61.
72% of the market share
.
Sales of terminal octreotide in China's public medical institutions (unit: 10,000 yuan) Source: Mynet.
com China's public medical institutions' terminal competition pattern.
Domestically marketed octreotide products include octreotide acetate injection, octreotide acetate for injection, and octreotide acetate microspheres for injection
.
Among them, there are as many as 17 manufacturers of octreotide acetate injection, but only three companies, including Sihuan Pharmaceutical, Sinopharm Yixin Pharmaceutical, and Suzhou Tianma Pharmaceutical, have been evaluated
.
At present, there are still many companies whose supplementary applications for the consistency evaluation of octreotide acetate injection are under review, including Shanghai First Biochemical Pharmaceutical Co.
, Ltd.
, Xinghao Pharmaceutical Co.
, Ltd.
, Chengdu Shengnuo Biological Co.
, Ltd.
, Hainan Zhonghe Pharmaceutical Co.
, Ltd.
, and Wuhan Renfu Pharmaceutical Co.
, Ltd.
and so on
.
In addition, four companies including Huiyu Pharmaceutical, Fuan Pharmaceutical, Harbin Sanlian Pharmaceutical, and Hanyu Pharmaceutical have also submitted applications for the imitation of octreotide acetate injection in four categories
.
It is worth noting that octreotide acetate injection has met the requirements for centralized procurement and is expected to be included in the national centralized procurement in the future
.
Data source: Mi Neiwang database, NMPA
